Menu Search
Equities

Blueprint Medicines Corp

2L9:FRA

Blueprint Medicines Corp

Actions
  • Price (EUR)92.14
  • Today's Change4.14 / 4.70%
  • Shares traded113.00
  • 1 Year change+52.30%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 15:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Blueprint Medicines Corp grew revenues 22.22% from 204.04m to 249.38m while net income improved from a loss of 557.52m to a smaller loss of 506.98m.
Gross margin97.01%
Net profit margin-29.48%
Operating margin-23.54%
Return on assets-11.11%
Return on equity-49.65%
Return on investment-13.84%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Blueprint Medicines Corp fell by 43.38m. However, Cash Flow from Investing totalled 274.04m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 436.85m for operations while cash generated from financing totalled 119.23m.
Cash flow per share-1.82
Price/Cash flow per share--
Book value per share4.93
Tangible book value per share4.93
More ▼

Balance sheet in USDView more

Blueprint Medicines Corp has a Debt to Total Capital ratio of 55.25%, a lower figure than the previous year's 102.74%.
Current ratio3.32
Quick ratio3.27
Total debt/total equity1.23
Total debt/total capital0.5525
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.